Pharmaceutical - Inflammatory diseases


Current filters:

Inflammatory diseases

Popular Filters

26 to 50 of 54 results

XOMA's partner Servier launches proof-of-concept clinical program for gevokizumab


US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker…

Anti-Arthritics/RheumaticsgevokizumabInflammatory diseasesPharmaceuticalResearchServierXOMA Corp

Questcor Pharma pays $60 million upfront to Novartis for rights to Synacthen


USA-based Questcor Pharmaceuticals (Nasdaq: QCOR) says it has acquired rights to develop Synacthen (tetracosactide)…

Inflammatory diseasesLicensingNovartisPharmaceuticalQuestor PharmaceuticalsSynacthen

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease


US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

US FDA approves Janssen's Simponi to treat ulcerative colitis


The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

European Patent Office maintains Pozen's PA/Vimovo patent


US drug firm Pozen (Nasdaq: POZN) says that the Opposition Division of the European Patent Office has…

AstraZenecaEuropeInflammatory diseasesPatentsPharmaceuticalPozenVimovo

SOBI links with Savient for co-promotion of Kineret in USA


Swedish Orphan Biovitrum (STO: SOBI) says it has entered into an agreement with USA-based Savient Pharmaceuticals…

Anti-Arthritics/RheumaticsInflammatory diseasesKineretLicensingMarkets & MarketingNorth AmericaPharmaceuticalSavient PharmaceuticalsSobiSwedish Orphan Biovitrum

Positive opinions for Novartis' Jetrea and Ilaris from EMA advisory panel


Among a number of positive recommendations last Friday from the European Medicines Agency's Committee…

Anti-Arthritics/RheumaticsEuropeIlarisInflammatory diseasesJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Savient's Krystexxa gets final EU approval for chronic tophaceous gout


US drugmaker Savient Pharmaceuticals (Nasdaq: SVNT) says that the European Commission has granted a marketing…

EuropeInflammatory diseasesKrystexxaPharmaceuticalRegulationSavient Pharmaceuticals

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen


Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Immune Pharmaceuticals to acquire EpiCept under stock merger accord


Privately-held Israeli company Immune Pharmaceuticals and US drug developer EpiCept Corp (Nasdaq: EPCT)…

EpiCeptImmune PharmaceuticalsInflammatory diseasesMergers & AcquisitionsOncologyPharmaceutical

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S


Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Takeda acquires vaccine maker LigoCyte; signs multi-drug discovery deal with Advinus


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it is to acquire privately-held US vaccine…

Advinus TherapeuticsInflammatory diseasesLicensingLigoCyteMergers & AcquisitionsMetabolicsNeurologicalPharmaceuticalTakeda PharmaceuticalsVaccines

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi


As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Evotec out-licenses EVT 401 in China to Conba Pharma


Hamburg, Germany-based Evotec AG (EVT: TecDAX) has granted a development and marketing license on EVT…

Asia-PacificConba PharmaceuticalsEvotecInflammatory diseasesLicensingPharmaceutical

MannKind licenses novel BTK inhibitors to Tolero Pharma


USA-based MannKind Corp (Nasdaq: MNKD) has granted an exclusive worldwide license to privately-held Tolero…

Inflammatory diseasesLicensingMannKindOncologyPharmaceuticalTolero Pharmaceuticals

Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research


Departing from its core competence, diabetes, Danish insulin giant Novo Nordisk (NOV: N) and the Kennedy…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceuticalResearch

26 to 50 of 54 results

Back to top